Green Thumb Industries Inc. (GTBIF)
OTCMKTS · Delayed Price · Currency is USD
8.99
+0.81 (9.90%)
Aug 13, 2025, 4:00 PM EDT
ASLAN Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2020 |
Revenue | 1,154 | 1,137 | 1,055 | 1,017 | 893.56 | 556.57 | Upgrade |
Revenue Growth (YoY) | 4.00% | 7.83% | 3.65% | 13.86% | 60.55% | 157.16% | Upgrade |
Cost of Revenue | 558.79 | 536.03 | 528.06 | 513.41 | 401.63 | 252.4 | Upgrade |
Gross Profit | 595.19 | 601.11 | 526.5 | 503.96 | 491.93 | 304.17 | Upgrade |
Selling, General & Admin | 413.09 | 376.23 | 336.4 | 292.98 | 272.34 | 198.06 | Upgrade |
Operating Expenses | 413.09 | 376.23 | 336.4 | 292.98 | 272.34 | 198.06 | Upgrade |
Operating Income | 182.1 | 224.88 | 190.1 | 210.99 | 219.59 | 106.11 | Upgrade |
Interest Expense | -20.68 | -24.27 | -19.07 | -21.2 | -21.98 | -18.67 | Upgrade |
Interest & Investment Income | 8.69 | 9.07 | 6.7 | 4.07 | 1.43 | 0.11 | Upgrade |
Earnings From Equity Investments | -10.02 | -8.69 | -1.17 | -4.26 | 1.8 | 2.32 | Upgrade |
Other Non Operating Income (Expenses) | 1.25 | 2.79 | 1.54 | 21.07 | 13.57 | -22.38 | Upgrade |
EBT Excluding Unusual Items | 161.34 | 203.78 | 178.1 | 210.67 | 214.41 | 67.5 | Upgrade |
Impairment of Goodwill | - | - | - | -57.37 | - | - | Upgrade |
Gain (Loss) on Sale of Investments | -3.36 | -3.19 | -17.87 | -12.32 | 5.96 | 26.37 | Upgrade |
Asset Writedown | -0.45 | -0.45 | -5.47 | -32.55 | -4.74 | - | Upgrade |
Other Unusual Items | - | - | 1.28 | - | -10.65 | 9.06 | Upgrade |
Pretax Income | 145.85 | 200.14 | 156.05 | 108.43 | 204.98 | 102.93 | Upgrade |
Income Tax Expense | 115.13 | 126.29 | 118.63 | 94.78 | 124.61 | 83.85 | Upgrade |
Earnings From Continuing Operations | 30.72 | 73.85 | 37.42 | 13.66 | 80.36 | 19.08 | Upgrade |
Minority Interest in Earnings | -1.76 | -0.77 | -1.15 | -1.68 | -4.93 | -4.09 | Upgrade |
Net Income | 28.96 | 73.08 | 36.27 | 11.98 | 75.44 | 14.99 | Upgrade |
Net Income to Common | 28.96 | 73.08 | 36.27 | 11.98 | 75.44 | 14.99 | Upgrade |
Net Income Growth | -55.80% | 101.51% | 202.78% | -84.12% | 403.14% | - | Upgrade |
Shares Outstanding (Basic) | 236 | 237 | 238 | 237 | 223 | 211 | Upgrade |
Shares Outstanding (Diluted) | 241 | 242 | 240 | 238 | 227 | 213 | Upgrade |
Shares Change (YoY) | 0.25% | 0.88% | 0.73% | 4.99% | 6.69% | 11.51% | Upgrade |
EPS (Basic) | 0.12 | 0.31 | 0.15 | 0.05 | 0.34 | 0.07 | Upgrade |
EPS (Diluted) | 0.11 | 0.30 | 0.15 | 0.05 | 0.33 | 0.07 | Upgrade |
EPS Growth | -59.71% | 100.00% | 200.00% | -84.85% | 371.43% | - | Upgrade |
Free Cash Flow | 127.61 | 115 | 4.93 | -20.94 | -55.8 | 36.12 | Upgrade |
Free Cash Flow Per Share | 0.53 | 0.47 | 0.02 | -0.09 | -0.25 | 0.17 | Upgrade |
Gross Margin | 51.58% | 52.86% | 49.93% | 49.54% | 55.05% | 54.65% | Upgrade |
Operating Margin | 15.78% | 19.78% | 18.03% | 20.74% | 24.57% | 19.06% | Upgrade |
Profit Margin | 2.51% | 6.43% | 3.44% | 1.18% | 8.44% | 2.69% | Upgrade |
Free Cash Flow Margin | 11.06% | 10.11% | 0.47% | -2.06% | -6.25% | 6.49% | Upgrade |
EBITDA | 298.63 | 338.09 | 290.89 | 307.65 | 288.04 | 158.61 | Upgrade |
EBITDA Margin | 25.88% | 29.73% | 27.58% | 30.24% | 32.24% | 28.50% | Upgrade |
D&A For EBITDA | 116.53 | 113.21 | 100.79 | 96.66 | 68.46 | 52.51 | Upgrade |
EBIT | 182.1 | 224.88 | 190.1 | 210.99 | 219.59 | 106.11 | Upgrade |
EBIT Margin | 15.78% | 19.78% | 18.03% | 20.74% | 24.57% | 19.06% | Upgrade |
Effective Tax Rate | 78.94% | 63.10% | 76.02% | 87.41% | 60.79% | 81.47% | Upgrade |
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.